Daniel Elías Martín Herranz’s Post

Fascinating summary of a complex topic from Daniel Elías Martín Herranz at Hurdle. It's exciting to see how existing data is being used to search for new cancer therapies. How long do you think it will be before we see the benefits of this Daniel Elías Martín Herranz? #biomarker #epigenetics #genetics

𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐢𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐚𝐫𝐞: 𝐓𝐡𝐞 𝐄𝐱𝐩𝐨𝐧𝐞𝐧𝐭𝐢𝐚𝐥 𝐆𝐫𝐨𝐰𝐭𝐡 𝐨𝐟 𝐭𝐡𝐞 𝐋𝐢𝐪𝐮𝐢𝐝 𝐁𝐢𝐨𝐩𝐬𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 As per the research data by Next Move Strategy Consulting, the global Liquid Biopsy Market size is predicted to reach $𝟏𝟓.𝟐𝟏 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 by 2030 with a 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟏𝟔.𝟒𝟒% from 2024-2030. The market is experiencing exponential growth, driven by revolutionary advancements in cancer detection and monitoring technologies. 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐑𝐄𝐄 𝐒𝐚𝐦𝐩𝐥𝐞: https://lnkd.in/dpqbAq8D Liquid biopsy plays a pivotal role in the era of personalized medicine, facilitating the identification of specific genetic mutations, biomarkers, and therapeutic targets associated with individual cancer patients. By providing real-time insights into the molecular profile of tumors, liquid biopsy guides treatment decisions, enabling oncologists to tailor therapies to the unique genetic characteristics of each patient's cancer. This personalized approach to cancer treatment improves treatment outcomes, minimizes adverse effects, and enhances patient quality of life, driving demand for liquid biopsy technologies in oncology clinics and research laboratories worldwide. Liquid biopsy technologies, such as next-generation sequencing (NGS), digital PCR, and single-cell analysis, are empowering researchers to study tumor heterogeneity, clonal evolution, and mechanisms of treatment resistance with unprecedented detail and precision. This deeper understanding of cancer biology is driving innovation in drug discovery, biomarker development, and precision oncology, accelerating the pace of progress towards more effective cancer therapies and personalized treatment strategies. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 - Bio-Rad Laboratories  - Biocept, Inc. - BillionToOne - F. Hoffmann-La Roche Ltd North America holds the lion share of liquid biopsy market. As the demand for non-invasive, real-time cancer diagnostics and personalized treatment options continues to rise, liquid biopsy technologies are expected to play an increasingly prominent role in oncology clinics, research laboratories, and pharmaceutical companies worldwide. #liquidbiopsy #cancertreatment #marketresearch #industrynews #healthcare

"Precision medicine has revolutionised cancer treatments; however, actionable biomarkers remain scarce. To address this, we develop the Oncology Biomarker Discovery (OncoBird) framework for analysing the molecular and biomarker landscape of randomised controlled clinical trials. OncoBird identifies biomarkers based on single genes or mutually exclusive genetic alterations in isolation or in the context of tumour subtypes, and finally, assesses predictive components by their treatment interactions. Here, we utilise the open-label, randomised phase III trial (FIRE-3, AIO KRK-0306) in metastatic colorectal carcinoma patients, who received either cetuximab or bevacizumab in combination with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI). We systematically identify five biomarkers with predictive components, e.g., patients with tumours that carry chr20q amplifications or lack mutually exclusive ERK signalling mutations benefited from cetuximab compared to bevacizumab. In summary, OncoBird characterises the molecular landscape and outlines actionable biomarkers, which generalises to any molecularly characterised randomised controlled trial." Interesting publication detailing an R software package for predictive biomarker identification in oncology clinical trials, by Alexander Ohnmacht, Michael Menden and larger team. Link to github repo and demo below: OncoBird is publicly available as a software package at https://lnkd.in/d-V99tph and a demo run is available at https://lnkd.in/dmS_DJV2. https://lnkd.in/da8V3Gxx

📃Scientific paper: Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the disulfiram metabolite CuET Abstract: Drug repurposing is a versatile strategy to improve current therapies. Disulfiram has long been used in the treatment of alcohol dependency and multiple clinical trials to evaluate its clinical value in oncology are ongoing. We have recently reported that the disulfiram metabolite diethyldithiocarbamate, when combined with copper (CuET), targets the NPL4 adapter of the p97VCP segregase to suppress the growth of a spectrum of cancer cell lines and xenograft models in vivo. CuET induces proteotoxic stress and genotoxic effects, however important issues concerning the full range of the CuET-evoked tumor cell phenotypes, their temporal order, and mechanistic basis have remained largely unexplored. Here, we have addressed these outstanding questions and show that in diverse human cancer cell models, CuET causes a very early translational arrest through the integrated stress response (ISR), later followed by features of nucleolar stress. Furthermore, we report that CuET entraps p53 in NPL4-rich aggregates leading to elevated p53 protein and its functional inhibition, consistent with the possibility of CuET-triggered cell death being p53-independent. Our transcriptomics profiling revealed activation of pro-survival adaptive pathways of ribosomal biogenesis (RiBi) and autophagy upon prolonged exposure to CuET, indicating potential feedback responses to CuET treatment. The latter concept was validated here by simultaneous pharmacological inhibition of RiBi and/or autophagy th... Continued on ES/IODE ➡️ https://etcse.fr/ecu ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 Size, Share & Trends Analysis Report By Application (Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head and Neck Cancer, Glioblastoma, Malignant Meningioma, Mesothelioma, Melanoma, Others), By Top Selling Drug (Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, Others), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028 IMIR Market Research™ 📚 𝐆𝐞𝐭 𝐬𝐚𝐦𝐩𝐥𝐞 𝐜𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐩𝐫𝐞𝐦𝐢𝐮𝐦 𝐫𝐞𝐩𝐨𝐫𝐭👇https://lnkd.in/dkywSjkz The cancer targeted therapy market is a segment within the broader field of oncology focused on developing and delivering therapies that specifically target cancer cells while sparing healthy cells. Targeted therapies aim to interfere with specific molecules involved in cancer cell growth and progression, such as proteins, genes, or enzymes. 𝘏𝘦𝘳𝘦 𝘢𝘳𝘦 𝘴𝘰𝘮𝘦 𝘬𝘦𝘺 𝘱𝘰𝘪𝘯𝘵𝘴 𝘢𝘣𝘰𝘶𝘵 𝘵𝘩𝘦 𝘤𝘢𝘯𝘤𝘦𝘳 𝘵𝘢𝘳𝘨𝘦𝘵𝘦𝘥 𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘮𝘢𝘳𝘬𝘦𝘵: 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐫𝐨𝐰𝐭𝐡:The market for cancer targeted therapies has been steadily growing due to advancements in understanding cancer biology and the development of novel targeted agents. Factors such as increasing cancer incidence, demand for personalized medicine, and technological advancements in drug development contribute to market growth. 𝐓𝐲𝐩𝐞𝐬 𝐨𝐟 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬: Targeted therapies can include small molecule drugs, monoclonal antibodies, antibody-drug conjugates, and other biologics. These therapies may target specific pathways or molecular targets involved in cancer growth, such as receptor tyrosine kinases, angiogenesis inhibitors, or immune checkpoint proteins. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬/𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐞𝐫𝐬 👇 SAYYIDA FATIMAH HOSPITAL, America Ambulance Service, Bloom Hospitals - The best place to get better, MNSTAR Group, Relay EMS ER 24/7 Plus, Jindal Hospital Bharatpur, HI TEK Super Speciality Hospital, Satpuda Engineering Pvt. Ltd., Piner's, Medic Care Services ,  Patriot Ambulance, Antelope Ambulance, Rockland Paramedic Services, St John Guernsey, Sparks & Ellis, Emcare Services, American EMS Blooming Grove Volunteer Ambulance Corps, CLINIQUE ADJIBADE Innomitra Elder Health Care Red Leaf  X-Emergency Services, PT Master Artha Kharisma, True North Emergency, Rabindra Surgicals Pvt Ltd, Anugrah Karya Indonesia PT, Trust Medical Group, PharmaCord Omega #cancercare #cancer #cancerawareness #cancersurvivor #cancertreatment #cancersupport #oncology #cancerfighter #cancersucks #breastcancer #cancerresearch #chemotherapy #health #cancerfree #cancersurvivors #cancerwarrior #beatcancer #healthcare #fightcancer #fuckcancer #cancerprevention

Really interesting progress in effort to target “intracellular T-cell checkpoints”. Work in Science Translational Medicine this week reporting advances in developing dual inhibitors of DGKA/Z as a new strategy for cancer immunotherapy. Potentially, a very important IO target that inhibits T-cell signaling, DGK A/Z has been tough to drug. The BMS team presents their elegant efforts to find a solution, with new inhibitors that appear very active in vitro and in vivo. These agents can potently enhance the function of both murine and human CD8+ T cells, including antigen-specific responses, rescue T-cell exhaustion in the LCMV model, and synergize with anti-PD1 in preclinical tumor models. Potentiate immune responses even with cell lines with low HLA class I expression. Will be interesting to watch where this approach goes. Side opinion: By my count, the field of IO has delivered approximately 24 new IO drugs in dozens of indications and counting in the past 10 years. The surface has only been scratched to date in my opinion. While remaining humble about what the field has learned from some very tough failures, we need to stay focused as we advance new orthogonal mechanisms, and generate the data that guides how to put them together correctly to the benefit of patients. The full potential of chemotherapy was realized in combinations, and ADCs represent the data-driven combination of a targeted antibody and a cytotoxic payload. We also learned this past week that an ADC combined with a checkpoint inhibitor is going to change the world for the treatment of bladder cancer. No different from other classes of agents, the full potential of IO over time will be unlocked by mechanism-based combinations arrived at by innovation, staying steady, and following the science. #cancer #oncology #immunooncology #immunotherapy #sitc #cancerimmunotherapy

🚀 𝑻𝒉𝒆 𝑭𝒖𝒕𝒖𝒓𝒆 𝒊𝒏 𝑶𝒏𝒄𝒐𝒍𝒐𝒈𝒚: 𝑭𝑫𝑨 𝑨𝒑𝒑𝒓𝒐𝒗𝒂𝒍 𝑻𝒓𝒆𝒏𝒅𝒔 📊 I might be a bit late to the party, but I wanted to highlight an interesting article posted a few months ago showcasing the trends in cancer therapies approved by the FDA. Here are a few key takeaways that got me thinking: 📈 𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐞𝐝 𝐑𝐚𝐭𝐞 𝐨𝐟 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬: The FDA has been giving the nod to cancer therapies at an increased rate, thanks to targeted therapies and immunotherapeutics. It's a testament to the power of basic research, where discoveries made decades ago are now making waves in clinical practice. The impact on oncology research is profound, with the increasing arsenal on offer to doctors offering more hope and options to patients battling late-stage cancer. 💨 𝐑𝐚𝐩𝐢𝐝 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐨𝐟 𝐈𝐦𝐦𝐮𝐧𝐞 𝐂𝐡𝐞𝐜𝐤𝐩𝐨𝐢𝐧𝐭 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 (𝐈𝐂𝐈𝐬): Just think about it – ICIs only entered the market in 2011, and yet, they've become the second most approved class of therapeutics since 2000. It's like starting a marathon when others are already 13 miles ahead and still managing to finish second! Names like pembrolizumab, nivolumab, and atezolizumab are leading the charge with 12 or more approvals each. Impressive, to say the least! 🎯 𝐂𝐲𝐭𝐨𝐭𝐨𝐱𝐢𝐜 𝐃𝐞𝐜𝐥𝐢𝐧𝐞: As targeted therapies and ICIs gain ground, traditional therapies like cytotoxic agents are seeing a decline. Maybe this is controversial, but I have never found it useful to label traditional chemotherapies 'cytotoxic' and newer therapies ‘targeted’. My skepticism makes me think some newer drugs just have better marketing than the old dogs. When you look into it, the traditional chemotherapies do often have clear targets and the ‘targeted’ therapies rarely have very clear, one-target mechanisms of action. 🔍 𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫-𝐃𝐫𝐢𝐯𝐞𝐧 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬: Nearly 39% of therapies are now approved for use within biomarker-defined cohorts – a substantial shift. This highlights the importance of understanding which patients benefit most from a drug, a lesson some early-stage therapeutics companies are still learning. Identifying markers of response and resistance before clinical trials is key, and with the rise of genomics and AI, we can expect this trend to grow. That's enough chatter from me! I'd love to hear your takeaways and experiences regarding the recent shifts in oncology and beyond. What trends have you noticed, and what excites you most about the future? Let's start a conversation! 👇 #FDAApprovals #CancerTherapies #MedicalTrends #HealthcareInnovation #OncologyResearch

Check out this recently published medical publication featured in the Journal of Clinical Oncology (JCO) Precision Oncology entitled “Afatinib plus bevacizumab treatment for a patient with EGFR S645C-mutant non-small cell lung cancer: A Case Report” led by Dr. Chia-I Shen, Dr. Ju-Chen Chang, Dr. Chiao-En Wu from Taiwan. Results of the study present real-world evidence for optimal therapeutic options for patients with lung cancer harbouring EGFR S645C mutations. https://lnkd.in/dGuSSV22 According to the authors of this study, these findings report for the first time a patient with advanced non-small cell lung cancer (NSCLC) harbouring EGFR S645C who benefitted from treatment with afatinib, an epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Based on the available preclinical study and this report, afatinib rather than osimertinib should be selected as the preferred TKI for advanced NSCLC patients with EGFR S645C. This study is especially relevant for the East Asian population as EGFR mutations are found in more than half of patients with lung adenocarcinoma in East Asia.¹ This study also reinforces the utility of comprehensive genomic profiling of all patients with NSCLC and suggests that comprehensive genomic profiling can detect very rare mutations which could be disease-causing and if targeted, patients can achieve better outcomes.    Congratulations to all the authors of this study led by Dr. Chia-I Shen, Dr. Ju-Chen Chang, Dr. Chiao-En Wu, Dr. Suyog Jain M.D. M.D. and Dr. Steve Olsen. Speak to your doctor today about comprehensive genomic testing with a simple blood draw. Visit us at https://lnkd.in/gHNdYtQN to find out more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer.  Reference: 1. Tan AC, Tan DSW: Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol 40:611-625, 2022 #guardanthealth #guardanthealthamea #liquidbiopsy #liquidissolid #medicalpublication #newpublication #medicalresearch #clinicalresearch #lungcancer #NSCLC #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #cancerpatients #medicaloncologists

𝐁𝐫𝐢𝐞𝐟 𝐆𝐮𝐢𝐝𝐞 𝐭𝐨 𝐒𝐨𝐥𝐢𝐝 𝐓𝐮𝐦𝐨𝐫 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐀 𝐏𝐃𝐅 𝐨𝐟 𝐭𝐡𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐢𝐚𝐥 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐢𝐬 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐚𝐭: https://lnkd.in/dEWCi-x9 The battle against cancer has been one of the most profound challenges in the field of medicine. Among the various types of cancer, solid tumors represent a significant portion of cases, and the pursuit of effective treatments continues to shape the healthcare landscape. The Global Solid Tumor Cancer Treatment Market is a dynamic and complex arena, marked by cutting-edge research, innovative therapies, and a commitment to improving patient outcomes. 𝐔𝐧𝐫𝐚𝐯𝐞𝐥𝐢𝐧𝐠 𝐭𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐱𝐢𝐭𝐲 𝐨𝐟 𝐒𝐨𝐥𝐢𝐝 𝐓𝐮𝐦𝐨𝐫 𝐂𝐚𝐧𝐜𝐞𝐫: Solid tumors, unlike blood-related cancers like leukemia, form in specific tissues or organs and present unique challenges due to their diverse origins and growth patterns. These tumors can arise in areas such as the lungs, breast, prostate, and brain, necessitating tailored approaches for each tumor type. Precision medicine, which involves targeting treatments based on a patient's specific genetic and molecular profile, has emerged as a key strategy in tackling these complex tumors. 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐏𝐫𝐨𝐠𝐫𝐞𝐬𝐬: Recent years have witnessed remarkable innovations in the field of solid tumor cancer treatment. Immunotherapy, for instance, has garnered significant attention for its ability to harness the body's immune system to fight cancer cells. Immune checkpoint inhibitors, a type of immunotherapy, have shown remarkable efficacy in various solid tumor types, often leading to long-lasting responses in patients who had limited treatment options before. Another avenue of progress is targeted therapy, where drugs are designed to specifically inhibit the molecular pathways that drive cancer growth. Genetic profiling of tumors helps identify specific mutations or alterations that can be targeted with these therapies, resulting in higher treatment precision and reduced side effects. 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐚𝐧𝐝 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬: Despite the promising strides, challenges persist within the global solid tumor cancer treatment market. Drug resistance, wherein cancer cells develop mechanisms to evade treatments, remains a significant hurdle. Additionally, accessing these advanced treatments can be a challenge in many regions due to high costs, limited healthcare infrastructure, and regulatory barriers. 𝐊𝐞𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 - AstraZeneca Amgen BKK B. Braun Melsungen AG Bristol-Myers Squibb Pharma Company Eli Lilly and Company STEPHEN F. HOFFMAN Merck & Co. Novartis Pfizer Olympus Medical Systems EMEA #solidtumorcancertreatment

𝐏𝐑𝐎𝐓𝐀𝐂𝐬: 𝐏𝐢𝐨𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 Delving into the realms of targeted protein degradation, I recently came across an insightful review article titled "Proteolysis-targeting chimeras (PROTACs) in cancer therapy" authored by Xinyi Li, Wenchen Pu, Qingquan Zheng, Min Ai, Song Chen, and Yong Peng, published in BMC Molecular Cancer. This comprehensive review sheds light on the principles, development, and advantages of PROTAC technology, presenting a promising approach for targeted therapy, especially in the context of cancer. 𝑷𝑹𝑶𝑻𝑨𝑪 𝑻𝒆𝒄𝒉𝒏𝒐𝒍𝒐𝒈𝒚: 𝑨 𝑮𝒂𝒎𝒆-𝑪𝒉𝒂𝒏𝒈𝒆𝒓 𝒊𝒏 𝑻𝒂𝒓𝒈𝒆𝒕𝒆𝒅 𝑻𝒉𝒆𝒓𝒂𝒑𝒚 The article introduces the revolutionary concept of PROTACs, engineered techniques designed for targeted protein degradation. By utilizing covalently-linked ligands, PROTACs recruit target proteins and E3 ubiquitin ligases, orchestrating their collaboration to induce proteasomal degradation through the ubiquitin-proteasome system. This innovative approach has emerged as a powerful strategy, overcoming limitations seen in traditional anti-cancer therapies. 𝑬𝒗𝒐𝒍𝒖𝒕𝒊𝒐𝒏 𝒐𝒇 𝑷𝑹𝑶𝑻𝑨𝑪𝒔: 𝑭𝒓𝒐𝒎 𝑪𝒐𝒏𝒄𝒆𝒑𝒕 𝒕𝒐 𝑪𝒍𝒊𝒏𝒊𝒄𝒂𝒍 𝑷𝒐𝒕𝒆𝒏𝒕𝒊𝒂𝒍 The review outlines the evolution of PROTAC technology, from Deshaies laboratory's pioneering work in 2001 to recent advancements in small molecule-based PROTACs. Notably, it explores the application of PROTACs in targeting critical oncoproteins, addressing challenges in molecular design, and emphasizing the potential for clinical applications. The commitment to open access principles underscores the collaborative nature of scientific progress. 𝑨𝒅𝒗𝒂𝒏𝒕𝒂𝒈𝒆𝒔 𝒂𝒏𝒅 𝑪𝒉𝒂𝒍𝒍𝒆𝒏𝒈𝒆𝒔 𝒊𝒏 𝑷𝑹𝑶𝑻𝑨𝑪 𝑫𝒆𝒗𝒆𝒍𝒐𝒑𝒎𝒆𝒏𝒕: 𝑨 𝑩𝒂𝒍𝒂𝒏𝒄𝒊𝒏𝒈 𝑨𝒄𝒕 The article meticulously discusses the advantages and challenges associated with PROTACs. Its event-driven mechanism, ability to degrade "undruggable" targets, and avoidance of compensatory protein expression highlight the advantages. However, challenges such as the "hook effect" and optimizing PROTAC structure for enhanced efficacy underscore the complexity of this innovative therapeutic approach. 𝑴𝒐𝒗𝒊𝒏𝒈 𝑻𝒐𝒘𝒂𝒓𝒅𝒔 𝑪𝒍𝒊𝒏𝒊𝒄𝒂𝒍 𝑰𝒎𝒑𝒂𝒄𝒕: 𝑭𝒖𝒕𝒖𝒓𝒆 𝑷𝒓𝒐𝒔𝒑𝒆𝒄𝒕𝒔 𝒐𝒇 𝑷𝑹𝑶𝑻𝑨𝑪𝒔 The review concludes by discussing the exciting prospects of PROTACs in clinical applications. Noteworthy is the initiation of the first-in-human trial by Arvinas Therapeutics Company in 2019, signaling a significant step toward translating PROTAC technology into tangible benefits for cancer patients. As at least 15 targeted degraders are expected to enter clinical trials by the end of 2021, the trajectory of PROTACs in cancer therapy looks promising. #PROTACs #PrecisionMedicine #CancerTherapy #OncologyInnovation #BMCMolecularCancer #TargetedTherapy #PROTACTechnology #CancerResearch #PrecisionOncology #MedicalInnovation #MolecularCancer #OncologyAdvances #ClinicalTrials